Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fate Therapeutics
University of Washington
Celgene
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)